410 results about "Unclassified Bacteria" patented technology

The invention relates to the methods for modifying the methylation pattern of bacteriophage DNA and phagemid DNA and to methods for selective killing of bacteria using lysogenic bacteriophages comprising bacteriophage DNA or phagemid DNA comprising components of an engineered CRISPR-Cas system.

The invention discloses a kit for quickly detecting 15 pneumonia pathogenic bacteria. The kit can detect streptococcus pneumoniae, staphylococcus aureus, haemophilus influenzae, mycoplasma pneumoniae, pseudomonas aeruginosa, baumanii, enterococcus faecalis, enterococcus faecium, klebsiella pneumoniae, escherichia coli, enterobacter cloacae, stenotrophomonas maltophilia, burkholderia cepacia, legionella pneumophila and chlamydia pneumoniae which cover clinically common pneumonia pathogenic bacteria difficult to culture. 16S rDNA and specific gene sequences corresponding to the pneumonia pathogenic bacteria are detected by combining gene chips with multiple asymmetric PCR reactions, and the categories of the bacteria in a to-be-detected sample are identified in genus and species. The kit makes up for the defect that current clinical detection of pneumonia pathogenic bacteria is not in time or comprehensive and a novel detection means for early diagnosis and early treatment of patients suffering from pneumonia is provided.

Methylotrophic or methanotrophic bacteria such as Methylobacterium are transformed with a gene of interest, and expression of the gene is regulated by means of a cumate repressor protein and an operator sequence which is operatively linked to the gene of interest, and the addition of an external agent. Specifically, the cymR repressor and cmt operator from Pseudomonas putida may serve to regulate gene expression in methylotrophic or methanotrophic bacteria with the addition of cumate.

The invention provides bacillus subtilis LFB112 with the collection number of CGMCC No.2996. The bacterial strain has relatively high antibacterial activity and has antibacterial effect on various animal pathogenic bacteria and food pathogenic bacteria. The invention also provides bacteriocin produced by the bacterial strain, wherein the bacteriocin is relatively stable against heat and acid and has a broad-spectrum antibacterial effect without inhibiting beneficial bacteria. Experiments indicate that the bacterial strain LFB112 provided by the invention and the bacteriocin produced by the same can be used for improving the clinical symptoms of chicken and increasing the growth speed and feed price, and can be used in biological veterinary medicaments or feed additives.

The present invention relates to a first group of novel bacterial and human associated oligonucleotides, here identified as Genomic Address Messenger or GAM oligonucleotide, and a second group of novel operon-like bacterial and human polynucleotides, here identified as Genomic Record or GR polynucleotide. GAM oligonucleotides selectively inhibit translation of known ‘target’ genes, many of which are known to be involved in various bacterial diseases. Nucleic acid molecules are provided respectively encoding 6444 GAM precursors oligonucleotides, and 726 GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.

L-amino acid is produced by culturing a bacterium belonging to the Enterobacteriaceae family which has L-amino acid-producing ability and is modified so that expression of the nhaA gene, nhaB gene, nhaR gene, chaA gene, mdfA gene, or combinations thereof is enhanced.

The invention relates to the technical field of biology, and discloses a coenzyme-Q10-production engineered bacteria construction method, engineered bacteria, and an application thereof. The method comprises the steps that: a, total genomic DNA is extracted from Rhodobacter sphaeroides cacterial liquid; b, UbiG gene is obtained by amplification with a polymerase chain reaction; c, the amplified UbiG gene is connected with broad-host plasmid, such that recombinant vector is constructed; d, the recombinant vector is transferred to Escherichia coli S17-1; and e, the Escherichia coli S17-1 is subjected to conjugal transfer with the Rhodobacter sphaeroides, such that the engineered bacteria are obtained. According to the method provided by the invention for improving coenzyme Q10 yield through regulating Rhodobacter sphaeroides aromatic ring modification pathway, the operation is simple, and coenzyme Q10 synthesis capacity can be improved by higher than 30%. The method is suitable for coenzyme Q10 large-scale industrial production.

The first primer of the invention is a primer which, when used in PCR under appropriate conditions, serves to detectably amplify 16S rRNA-encoding DNAs of bacteria of the Escherichia, Salmonella and Vibrio genera, but when used in PCR under the same conditions, does not serve to detectably amplify either chloroplast 16S rRNA-encoding DNAs or mitochondrial 16S rRNA-encoding DNAs. The second primer of the invention is a primer which, when used in PCR under appropriate conditions, serves to detectably amplify 16S rRNA-encoding DNAs of Staphylococcus aureus and Bacillus cereus, but when used in PCR under the same conditions, does not serve to detectably amplify either chloroplast 16S rRNA-encoding DNAs or mitochondrial 16S rRNA-encoding DNAs.

The invention provides strains of bacteria, especially enterotoxigenic E. coli, attenuated by mutations in the genes encoding enterotoxins (LT, ST, EAST1) and optionally further attenuated by deletion of additional chromosomal genes. In addition the invention provides strains of attenuated bacteria expressing immunogenic but non-toxic variants of one or more of these enterotoxins. These bacteria are useful as a vaccine against diarrhoeal disease.

A fire-resistant and acid-proof alpha-amylase and its production are disclosed. The process is carried out by separating precursor-alpha-amylase gene from lichenized bacillosporin, mutating for L134 and S320 amino acid residues and high-efficient expressing alpha-amylase mutant in bacterium. It achieves better safety, expression and acid stability, and more yield.

The invention relates to the field of biotechnology, and particularly relates to a shuttle plasmid vector, as well as a construction method and applications thereof. The shuttle plasmid vector can shuttle in yeast and Escherichia coli, and the nucleotide sequence of the shuttle plasmid vector is shown in SEQ ID NO.1. Compared with the prior art, he shuttle plasmid vector realizes the shuttling in yeast and bacteria, and has the capabilities of homologous recombination cloning, self replication and recombinant screening in yeast, as well as the characteristics of being stable in replication and maintenance and convenient for DNA purification and separation in bacteria.

The invention provides a truncated-form streptococcus hemolyticus bacteriolysin O gene and an ASO detection kit. According to the invention, part of SLO gene fragments are cloned, and the part of SLO genes are cloned into an expression vector of escherichia coli and the like so as to realize mass expression and facilitate purification. In particular, the invention provides a DNA sequence which has a base sequence as shown in SEQ ID NO:1. According to the invention, the truncated-form SLO sequence can greatly improve the yield of SLO protein; more than 150 mg of SLO protein can be obtained through purification of one liter of bacterial culture, and the purity is more than 90%; immunological tests prove that the sectionally expressed SLO still maintains the specific immunogenicity.

The invention relates to a process for the production of L-amino acids, in which the following steps are carried out: a) fermentation of the coryneform bacteria producing the desired L-amino acid, in which at least the mqo gene is attenuated, b) concentration of the desired L-amino acid in the medium or in the cells of the bacteria, and c) isolation of the L-amino acid, and, optionally, bacteria are used in which further genes of the biosynthesis pathway of the desired L-amino acid are additionally enhanced, or bacteria are used in which at least some of the metabolic pathways reducing formation of the desired L-amino acid are excluded.

The invention relates to a method for detecting bacteria, in particular to a method for detecting enteritis pathogenic bacteria. The method comprises the following steps of: (1) extracting DNA (Deoxyribonucleic Acid) of one or more bacteria samples; (2) amplifying full length of 16S rDNA (ribosomal DNA) of a sample by using a primer of 16S rDNA of bacteria; (3) breaking an amplified PCR (Polymerase Chain Reaction) product; (4) repairing ends of the broken product from each bacteria sample and connecting deoxyadenosine at the end 3' of the product, and then connecting different PCR-free joints; (5) sequencing a connection product by using a second-generation sequencing technology to obtain a sequence of the connection product; and (6) comparing the sequence with 16S rDNA reference sequences of all existing bacteria to determine types of bacteria existing in each sample.

The invention discloses antibacterial peptides and application of the antibacterial peptides to preparation of a medicament resisting drug-resistant bacteria. The antibacterial peptides consist of 21 amino acids, wherein the amino acid sequence is shown as SEQIDNO.1. The in-vivo and in-vitro research shows that six kinds of antibacterial peptides have a strong inhibiting and killing action for the mostly clinically-separated drug-resistant bacteria and can remarkably reduce the mortality of a septicemia model caused by the drug-resistant bacteria; and a hemolytic test and an acute local stimulus test results show that six kinds of derivates have no hemolytic test or acute toxic stimulus reaction when the concentration is 2.5mg/mL.

The invention discloses polypeptide and a preparation method and application thereof with an anti-bacterial function and belongs to the technical field of anti-bacteria. The antibacterial polypeptide comprises amino acid sequences as shown in the SEQ ID NO.1 and salt or ester thereof. The antibacterial polypeptide forms an alpha spiral structure through the specific array of specific kinds of amino acid, the spiral structure makes contact with and acts on a bacterial cell wall to cause the piercing of the cell wall, the bacterium dies, and therefore the antibacterial effect is achieved. The antibacterial polypeptide is convenient to composite, low in cost, good in effect and safe and reliable. Meanwhile, protein antibacterial agents can effectively reduce the occurrence of bacterial drug resistance, and huge potential is achieved in the direction of replacing antibiotics to be the main stream antibacterial medicine.

The invention provides a group of peptide nucleic acid-cell penetrating peptide antisense antibacterial sequences taking bacterial gene rpoD as a target. The cell penetrating peptide-mediated antibacterial RNA polymerase sigma 70 factor gene rpoD which is antisense nucleic acid of a specificity target can selectively inhibit the expression of in-vivo ropD genes of Gram-negative bacterium (containing sensitive and multidrug resisting clinical pathogenicity Escherichia coli, salmonellatyphimurium, Klebsiella pneumoniae and pseudomonas aeruginosa) or gram-positive bacterium (containing sensitiveand multidrug resisting staphylococcus aureus) and further inhibit bacteria growth and reproduction, thus having the advantages of good antibacterial effect, low toxicity, good stability and better tolerance. The invention also discloses a chemical preparation method of a peptide nucleic acid-cell penetrating peptide solid phase. The antibacterial peptide synthesized in the invention can be used for preparing multidrug-resistant bacteria infection proofing antisense drugs and has the potency of being developed into a broad-spectrum antisense antibacterial agent which is expressed by efficiently transferred and peculiarly blocked bacterium disease-causing genes.

Nucleotide sequences from coryneform bacteria which code for the cysD, cysN, cysK, cysE and cysH genes and a process for the fermentative preparation of amino acids using bacteria in which the genes mentioned are enhanced, a process for the fermentative preparation of L-amino acids using coryneform bacteria in which at least the cysD gene, the cysN gene, the cysK gene, the cysE gene and/or the cysH gene is present in enhanced form, and the use of polynucleotides which contain the sequences according to the invention as hybridization probes and a process for the preparation of an L-methionine-containing animal feedstuffs additive from fermentation broths.

Rediced genome or native K12 strain E. coli bacteria comprising expression vectors encoding a recombinant CRM197 protein and their use in the production of CRM 197 is provided. The CRM 197 protein may be fused to a signal sequence that directs the expressed CRM197 protein to the periplasm of the E. coli host.